Barinthus Biotherapeutics (BRNS) News Today → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free BRNS Stock Alerts $2.32 -0.03 (-1.28%) (As of 05:12 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13 at 2:33 PM | investorplace.comBRNS Stock Earnings: Barinthus Biotherapeutics Beats EPS for Q1 2024May 13 at 8:00 AM | globenewswire.comBarinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate DevelopmentsMay 13 at 6:09 AM | americanbankingnews.comBarinthus Biotherapeutics plc (NASDAQ:BRNS) Short Interest Up 34.8% in AprilMay 11 at 4:54 AM | americanbankingnews.comBarinthus Biotherapeutics (NASDAQ:BRNS) Stock Price Down 2.6%May 7, 2024 | americanbankingnews.comBarinthus Biotherapeutics (NASDAQ:BRNS) and Ayala Pharmaceuticals (NASDAQ:ADXS) Head-To-Head ReviewMay 4, 2024 | finance.yahoo.comIncreases to CEO Compensation Might Be Put On Hold For Now at Barinthus Biotherapeutics plc (NASDAQ:BRNS)May 1, 2024 | globenewswire.comBarinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical OfficerApril 27, 2024 | marketbeat.comBarinthus Biotherapeutics plc (NASDAQ:BRNS) Short Interest Up 39.6% in AprilBarinthus Biotherapeutics plc (NASDAQ:BRNS - Get Free Report) saw a significant increase in short interest in the month of April. As of April 15th, there was short interest totalling 14,100 shares, an increase of 39.6% from the March 31st total of 10,100 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average trading volume of 22,000 shares, the short-interest ratio is currently 0.6 days.April 19, 2024 | marketbeat.comBarinthus Biotherapeutics (NASDAQ:BRNS) Given "Buy" Rating at HC WainwrightHC Wainwright restated a "buy" rating and set a $8.00 price target on shares of Barinthus Biotherapeutics in a research note on Friday.April 19, 2024 | markets.businessinsider.comInfection-Focused Barinthus Bio's VTP-200 Data Underwhelming: Analyst Weighs On Mixed PerspectivesApril 18, 2024 | globenewswire.comBarinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) InfectionsApril 14, 2024 | marketbeat.comShort Interest in Barinthus Biotherapeutics plc (NASDAQ:BRNS) Drops By 15.1%Barinthus Biotherapeutics plc (NASDAQ:BRNS - Get Free Report) was the recipient of a large decrease in short interest in the month of March. As of March 31st, there was short interest totalling 10,100 shares, a decrease of 15.1% from the March 15th total of 11,900 shares. Based on an average daily trading volume, of 21,400 shares, the short-interest ratio is currently 0.5 days. Currently, 0.0% of the company's stock are short sold.April 14, 2024 | seekingalpha.comBRNS Barinthus Biotherapeutics plcMarch 22, 2024 | finance.yahoo.comBarinthus Biotherapeutics Reports Significant Financial Shifts and Clinical Progress in 2023March 22, 2024 | marketbeat.comWilliam Blair Comments on Barinthus Biotherapeutics plc's Q1 2025 Earnings (NASDAQ:BRNS)Barinthus Biotherapeutics plc (NASDAQ:BRNS - Free Report) - William Blair issued their Q1 2025 EPS estimates for shares of Barinthus Biotherapeutics in a report released on Wednesday, March 20th. William Blair analyst A. Hsieh forecasts that the company will post earnings per share of ($0.71) forMarch 21, 2024 | marketbeat.comBarinthus Biotherapeutics (NASDAQ:BRNS) Given New $8.00 Price Target at HC WainwrightHC Wainwright decreased their target price on shares of Barinthus Biotherapeutics from $15.00 to $8.00 and set a "buy" rating on the stock in a research report on Thursday.March 20, 2024 | benzinga.comBarinthus Biotherapeutics: Q4 Earnings InsightsMarch 20, 2024 | globenewswire.comBarinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate DevelopmentsMarch 4, 2024 | finance.yahoo.comIndividual investors account for 48% of Barinthus Biotherapeutics plc's (NASDAQ:BRNS) ownership, while institutions account for 25%February 29, 2024 | marketbeat.comBarinthus Biotherapeutics plc (NASDAQ:BRNS) Short Interest UpdateBarinthus Biotherapeutics plc (NASDAQ:BRNS - Get Free Report) saw a significant drop in short interest in February. As of February 15th, there was short interest totalling 14,100 shares, a drop of 55.8% from the January 31st total of 31,900 shares. Based on an average trading volume of 12,000 shares, the short-interest ratio is currently 1.2 days. Currently, 0.0% of the shares of the stock are short sold.February 25, 2024 | benzinga.comBarinthus Biotherapeutics Stock (NASDAQ:BRNS) Dividends: History, Yield and DatesFebruary 23, 2024 | marketbeat.comBarinthus Biotherapeutics (NASDAQ:BRNS) Shares Up 3.1%Barinthus Biotherapeutics (NASDAQ:BRNS) Stock Price Up 3.1%January 10, 2024 | marketbeat.comBarinthus Biotherapeutics plc to Post FY2023 Earnings of ($2.03) Per Share, HC Wainwright Forecasts (NASDAQ:BRNS)Barinthus Biotherapeutics plc (NASDAQ:BRNS - Free Report) - Stock analysts at HC Wainwright boosted their FY2023 earnings per share (EPS) estimates for shares of Barinthus Biotherapeutics in a research report issued on Monday, January 8th. HC Wainwright analyst Y. Chen now forecasts that the compJanuary 8, 2024 | marketbeat.comBarinthus Biotherapeutics (NASDAQ:BRNS) Earns "Outperform" Rating from William BlairWilliam Blair reiterated an "outperform" rating on shares of Barinthus Biotherapeutics in a research report on Monday.November 7, 2023 | marketbeat.comTrading was temporarily halted for "BRNS" at 10:11 AM with a stated reason of "LULD pause." Get Barinthus Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BRNS and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s “Tax Free” Retirement Strategy (Ad)Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem. Protect your retirement savings from the inevitable devaluation of the dollar… BRNS Media Mentions By Week BRNS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BRNS News Sentiment▼0.750.57▲Average Medical News Sentiment BRNS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BRNS Articles This Week▼81▲BRNS Articles Average Week Get Barinthus Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BRNS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ANIX News Today SPRO News Today BYSI News Today CMRX News Today MIST News Today CUE News Today ONCY News Today ADAG News Today PRPH News Today YS News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BRNS) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperDid Intel Just Dethrone Nvidia?Chaikin AnalyticsTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsAmerica’s worst nightmare?Porter & CompanyElon’s New Device is About to Shock the WorldInvestorPlaceClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Barinthus Biotherapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
